Pharmaceuticals

Xiao Fang Pharma

Xiao Fang Pharma released FY2026 Q1 earnings on April 27 After-Market (BJT), actual revenue CNY 145.69 M, actual EPS CNY 0.35

Xiao Fang Pharma FY2026 Q1 Earning Release on April 28 After-Market (BJT)

Xiao Fang Pharma FY2025 Annual Earnings Release on April 22, 2026 After-Market (BJT)

Xiao Fang Pharma FY2025 Q3 Earnings Release on October 25 After-Market BJT

Xiao Fang Pharma released FY2025 9 Months Earnings on October 10 After-Market (BJT), actual revenue CNY 397.22 M, actual EPS CNY 1.0506

Xiao Fang Pharma released FY2025 Q3 earnings on October 10 After-Market (BJT), actual revenue CNY 127.43 M, actual EPS CNY 0.3006

Xiao Fang Pharma released FY2024 Semi-Annual Earnings on August 25 (BJT), actual revenue CNY 261.79 M, actual EPS CNY 0.99

Xiao Fang Pharma released FY2025 Q2 earnings on August 25 During-Market BJT, actual revenue CNY 140.72 M, actual EPS CNY 0.38

Xiao Fang Pharma released FY2025 Semi-Annual Earnings on August 25 During-Market (BJT), Actual Revenue: CNY 269.79 M, Actual EPS: CNY 0.75

Xiao Fang Pharma to Release FY2025 Semi-Annual Earnings on August 26, 2025 (BJT)

Xiao Fang Pharmaceutical Signs Cooperation Agreement with Shanghai Skin Disease Hospital on Compound Side 柏 Decoction

Xiafang Pharmaceutical releases Q1 2025 financial report

Xiao Fang Pharma released FY2024 Q4 earnings on April 29 After-Market BJT, actual revenue CNY 107.37 M, actual EPS CNY 0.2764

Xiao Fang Pharma released FY2024 earnings on April 29 After-Market BJT, actual revenue CNY 474.58 M, actual EPS CNY 1.53

Xiao Fang Pharma released FY2025 Q1 earnings on April 29 After-Market (BJT), actual revenue CNY 129.07 M, actual EPS CNY 0.37

Xiao Fang Pharmaceutical to Release FY2025 Q1 Earnings on April 30 After-Market BJT

Xiao Fang Pharmaceutical FY2024 Earnings Release Scheduled for April 30, 2025 After-Market BJT

Xiao Fang Pharma released FY2024 Q3 earnings on October 28 After-Market (BJT), actual revenue CNY 105.43 M, actual EPS CNY 0.3085

Xiao Fang Pharma released FY2024 9 Months earnings on October 28 After-Market (BJT), actual revenue CNY 367.21 M, actual EPS CNY 1.2973

Shanghai Xiao Fang Pharmaceutical to Announce Q3 2024 Earnings on Oct 29, 2024

159615

520880

588130

603207

Hong Kong customs seized over 14,000 smuggled weight-loss injections valued at approximately HK$56 million (US$7.2 million) destined for Macau. The injections, labeled "Mounjaro" by Japan's Tanabe Pharma, were found on a river trade vessel along with other smuggled goods. Customs is investigating the authenticity of the products and potential syndicate operations, as these slimming jabs require a prescription in Hong Kong. Concerns have been raised about the illegal sale of such medications online and their associated health risks.

SCMP

China Southern Hang Seng Biotech ETF(QDII)

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

ChinaAMC SSE STAR Biology and Medicine ETF

E Fund CSI Biotechnology Theme ETF

CISI FIN B2702

E Fund Hang Seng SCHK Innovative Drug ETF

ChinaAMC CSI Biotechnology Theme ETF

Penghua SSE STAR Biology and Medicine ETF

China Merchants CSI Biotechnology Theme ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Penghua CSI HK Connect Health Care Composite ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

Ping An CSI Medicine and Medical Device Innovation ETF

ChinaAMC SSE Health Care ETF Initiating Fund

E Fund CSI 300 Health Care ETF

Minsheng Royal CSI Biotechnology Theme ETF

Tianhong CNI BIOMEDICINE ETF

Yinhua CSI Innovative Drugs Industry ETF

Guotai CSI Bio-medicine ETF

Bosera Hang Seng Health Care ETF(QDII)

Huaan Hang Seng Biotech ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

Yinhua CSI Research Sector 100 ETF

Hong Kong customs seizes 14,080 smuggled slimming jabs bound for Macau

On October 24th, Xiao Fang Pharma released its Q3 2025 report, with third-quarter operating revenue of 127 million yuan, a year-on-year increase of 20.87%; net profit of 49.0727 million yuan, a year-on-year increase of 14.51%. For the first three quarters, operating revenue was 397 million yuan, a year-on-year increase of 8.17%; net profit was 170 million yuan, a year-on-year increase of 5.09%; basic earnings per share were 1.06 yuan

Zhitong

Xiao Fang Pharma: Net profit in the first three quarters increased by 5.09% year-on-year

301004

300274

Wind data shows that, according to the equity distribution plans of listed companies, 18 A-shares will have their equity registration today. Among them, 18 stocks plan to distribute dividends. In terms of dividend distribution, the equity registration date for the 18 stocks is October 17. CAYI, Sungrow Power Supply, and Xiao Fang Pharma have the highest dividend payouts, distributing 10.00 yuan, 9.50 yuan, and 7.00 yuan per 10 shares, respectively

CAYI Group

Sungrow Power Supply

Overview of A-share dividends and stock distributions: 18 stocks have their equity registration today

300404

Xiao Fang Pharma and BOJI CRO signed a technical entrustment contract, in which BOJI CRO will assist in completing the clinical research and registration of the traditional Chinese medicine Class 1 new drug "Compound Arborvitae Tincture." This cooperation marks an important progress for Xiao Fang Pharma in the field of innovative drugs, as both parties will leverage their respective advantages to enhance R&D efficiency and lay the foundation for product launch

BOJI CRO

Xiao Fang Pharma entrusts BOJI CRO to develop traditional Chinese medicine Class 1 new drug "Compound Arborvitae Tincture" (indication for hair loss)

688439

603535

On Tuesday, 7 companies had their restricted shares unlocked, with a total unlock volume of 149 million shares and an unlock market value of 6.802 billion yuan. GUIZHOU ZHENHUA FENGGUANG SEMICONDUCTOR, Jiacheng International, and Xiao Fang Pharma had the highest unlock volumes, at 86.0824 million shares, 33.2236 million shares, and 14.4 million shares, respectively. In terms of unlock market value, GUIZHOU ZHENHUA FENGGUANG SEMICONDUCTOR, Xiao Fang Pharma, and Jiacheng International were 5.238 billion yuan, 512 million yuan, and 417 million yuan, respectively. The unlock ratio for GUIZHOU ZHENHUA FENGGUANG SEMICONDUCTOR exceeded 10%, reaching 43.04%

GUIZHOU ZHENHUA FENGGUANG SEMICONDUCTOR

Jiacheng International

Overview of A-share lock-up stock release: Lock-up stocks worth 6.802 billion yuan are released today

According to the Zhitong Finance APP, Xiao Fang Pharma disclosed its semi-annual report for 2025. During the reporting period, the company achieved revenue of 270 million yuan, a year-on-year increase of 3.06%; net profit attributable to shareholders was 121 million yuan, a year-on-year increase of 1.69%; net profit excluding non-recurring items was 121 million yuan, a year-on-year increase of 2.04%; basic earnings per share were 0.75 yuan. The company plans to distribute a cash dividend of 7.00 yuan (including tax) for every 10 shares to all shareholders

Xiao Fang Pharma released its semi-annual performance, with a net profit attributable to the parent company of 121 million yuan, a year-on-year increase of 1.69%

Xiao Fang Pharma has signed a cooperation development agreement with Shanghai Dermatology Hospital to jointly develop a new traditional Chinese medicine compound, Cedar Extract, for the treatment of hair loss. This drug has the effects of cooling the blood, promoting circulation, and stimulating hair growth. It has accumulated efficacy and safety data in clinical applications, mainly used for treating various types of hair loss, with broad prospects and is expected to become the first traditional Chinese medicine preparation for hair loss in China

Yinhua CSI Chinese Medicine ETF

Xiao Fang Pharma plans to collaborate with Shanghai Dermatology Hospital to develop a Class 1 new traditional Chinese medicine for treating hair loss, a compound of cedar tincture

According to the announcement from Xiao Fang Pharmaceutical, the company's board of directors believes that the granting conditions for the restricted stock incentive plan for 2025 have been met. The initial grant date for this incentive plan is set for February 13, 2025, and it has been agreed to grant 1.28 million shares of restricted stock to 178 incentive recipients at a grant price of 14.97 yuan per share

Xiao Fang Pharmaceutical grants 1.28 million restricted shares to 178 incentive recipients

According to the Zhitong Finance APP, Xiao Fang Pharmaceutical has released a draft of the 2025 Restricted Stock Incentive Plan, which proposes to grant a total of no more than 1.6 million restricted shares, accounting for 1.00% of the company's total equity at the time of the announcement of this incentive plan draft. The grant price for the first issuance of restricted shares under this incentive plan is set at 14.97 yuan per share. The number of incentive recipients for the first grant under this incentive plan will not exceed 178 individuals

Xiao Fang Pharmaceutical plans to launch a restricted stock incentive plan in 2025, with a total not exceeding 1.6 million shares

002038

The chemical pharmaceutical concept experienced partial fluctuations, with Xiao Fang Pharmaceutical and SL PHARM hitting the daily limit, Hendi Pharmaceutical rising over 10%, and LuKang Pharmaceutical, TuoXin Pharmaceutical, and New Hope Liuhe following suit

SL PHARM

LKPC

Tuoxin Pharmaceutical

BIOCAUSE HEILEN PHARMA

Chemical pharmaceutical concept experiences partial fluctuations, Xiao Fang Pharmaceutical and SL PHARM hit the limit up

Xiao Fang Pharma(603207.SH)